Preview

"Arterial’naya Gipertenziya" ("Arterial Hypertension")

Advanced search

CHANGES IN IMPEDANCE AGREGATOMETRY IN PATIENTS WITH A HISTORY OF STROKE RECEIVING ANTIPLATELET DRUGS

https://doi.org/10.18705/1607-419X-2017-23-6-507-516

Abstract

Objective. To study the changes of impedance agregatometry indicators in patients with a history of stroke receiving antiplatelet therapy. Design and methods. We analyzed 324 medical records of patients with cerebrovascular events in past. Among them 252 patients (77,7 %) took aspirin, 53 patients (16,4 %) — clopidogrel and 19 patients (5,9 %) received in dual antiplatelet therapy. Simultaneously, all patients were treated with standarddose antihypertensives and statins for secondary prevention. In all patients the impedance agregatometry was performed (CHRONO-LOG, USA, Model 590). The platelet function in whole blood was evaluated with the use of adenosine diphosphate (ADP, final concentration — 10 pM/ml) and collagen (2 mg/ml) as inductors. The results were compared with the reference values intervals used in the diagnostic laboratory of urban advisory diagnostic center № 1 of St. Petersburg. Results. The patients treated with aspirin show an increase in time of the beginning of platelet aggregation up to 74,0 ± 1,1 (71,8–76,2) s and a platelet aggregation area under curve (AUC) decrease to 53,8 ± 1,1 (51,7–55,9) om × s when collagen is used as an inducer. The patients receiving clopidogrel 75 mg once daily demonstrate a decrease in amplitude of platelet aggregation to 8,8 ± 0,8 (7,1–10,5) om and AUC to 37,6 ± 3,5 (30,5–44,7) om × s when adenosindiphosphate (ADF) is used as the inductor. Also clopidogrel (75 mg/day) therapy is associated with the prolongation of time of aggregation onset (Lag Time) to 76,9 ± 5,3 (66,3–87,5) s, and with the decrease in AUC to 53,6 ± 2,9 (47,4–59,5) om × s when collagen is used as the inductor. Conclusions. The impedance agregatometry may be used to assess the impact of antiplatelet drugs on platelet aggregation in out-patients with a history of stroke.

About the Authors

O. V. Rodionova
First Pavlov State Medical University of St. Petersburg.
Russian Federation

Olga V. Rodionova, MD, Neurologist, Neurological Department № 1, Research Institute, Neurology Clinic.

St. Petersburg.



V. A. Sorokoumov
First Pavlov State Medical University of St. Petersburg.
Russian Federation

Viktor A. Sorokoumov, MD, PhD, DSc, Professor, Department of Neurology.

St. Petersburg.



T. V. Vavilova
Almazov National Medical Research Centre; City Consultation and Diagnostic Center № 1.
Russian Federation

Tatyana V. Vavilova, MD, PhD, Head, Department of Clinical Laboratory Diagnostics and Genetics, Almazov National Medical Research Centre, Chief Out-of-Staff Specialist of Clinical Laboratory Diagnostics of the Northwestern Federal District, Hematologist, City Consultation and Diagnostic Center № 1.

St. Petersburg.



Yu. D. Bogatenkova
City Consultation and Diagnostic center № 1.
Russian Federation

Yuliya D. Bogatenkova, MD, PhD, Neurologist, Head, Neurological Department.

St. Petersburg.



M. M. Mnuskina
City Consultation and Diagnostic center № 1.
Russian Federation

Marina M. Mnuskina, MD, Head, Clinical and Diagnostic Laboratory.

St. Petersburg.



I. G. Krupotkina
City Consultation and Diagnostic center № 1.
Russian Federation

Irina G. Krupotkina, PhD in Biology, Physician, Clinical and Diagnostic Laboratory.

St. Petersburg.



L. A. Isaeva
City Consultation and Diagnostic center № 1.
Russian Federation

Lyudmila A. Isaeva, MD, Physician, Clinical and Diagnostic Laboratory.

St. Petersburg.



References

1. Гусев Е. И., Скворцова В. И., Стаховская Л. В. Проблема инсульта в РФ: время активных совместных действий. Журнал неврологии и психиатрии имени С. С. Корсакова. 2007;8:4–10. [Gusev EI, Skvortsova VI, Stakhovskaya LV. The problem of stroke in Russia: the time of active joint action. Zh Nevrol Psikhiatr im S S Korsakova. 2007;8:4–10. In Russian].

2. Стаховская Л. В., Клочихина О. А., Богатырева М. Д., Коваленко В. В. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009–2010 гг.). Журнал неврологии и психиатрии имени С. С. Корсакова. 2013;5:4–10. [Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. Epidemiology of stroke in Russia according to the results of territorial and population register (2009–2010). Zh Nevrol Psikhiatr im S S Korsakova. 2013;5:4–10. In Russian].

3. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J. 2002;324(7329):71–86.

4. Скворцова В. И., Шаманов Н. А. Вторичная профилактика. Антитромботическая терапия. В: Рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками: Бионика; 2008. 35 с. [Skvortsova VI, Shamanov NA Secondary prevention. Antithrombotic Therapy. Guidelines for management of ischaemic stroke and transient ischaemic attack. Bionica, 2008. p. 35. In Russian].

5. Марцевич С. Ю., Кутишенко Н. П., Гинзбург М. Л., Малышева А. М., Полянская Ю. Н. Антиагрегантная терапия у больных с высоким риском развития тромботических осложнений: проблема эффективности, безопасности и приверженности. Клиницист. 2011;2:72–79. [Martsevich SU, Kutishenko NP, Ginzburg ML, Malysheva AM, Polyanskaya UN. Antiplatelet therapy in patients with high risk of thrombotic complications: the problem of efficiency, safety and commitment. Clinitsist = The Clinician. 2011;2:72–79. In Russian].

6. Chen S, Shen Q, Tang Y, He L, Li Y, Li H et al. Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. Plos One. 2014;9(8):1–10. doi:10.1371/journal.pone.0104402

7. Заключение междисциплинарного Совета экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами, Национального научного общества воспаления. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Рациональная фармакотерапия в кардиологии. 2014;10(6):679– 687. [The conclusion of the Council of multi-disciplinary experts of the Russian Society of Angiology and Vascular Surgery, Russian Scientific Society of endovascular diagnostics and treatment, the National Association for fighting strokes, the National Scientific Society of inflammation. The role of testing platelet functional activity in the prevention of cardiovascular events in patients receiving antiplatelet therapy. Rational pharmacotherapy in cardiology. 2014;10(6):679–687. In Russian].

8. Столяр М. А., Ольховский И. А. Определение аспиринорезистентности тромбоцитов in vitro по данным оптического и импедансометрического методов. Вестник НГУ: серия биология, клиническая медицина. 2012;10(5):36–42. [Stolyar MA, Olkhovskiy IA. Evaluation of aspirin platelet resistance in vitro according to the optical and impedance metric methods. Bulletin of NSU: a series of biology, clinical medicine. 2012;10(5):36–42. In Russian].

9. Ferguson A, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability review of the published literature. Texas Heart Inst J. 2008;35(3):313–320.

10. Oxley TJ, Dowling RJ, Mitchell PJ, Davis S, Yan B. Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Frontiers in Neurology. 2011;2:89. doi:10.3389/fneur.2011.00083

11. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009:227–233. doi:10.1016/j.amjcard.2009.03.022

12. Приказ Министерства здравоохранения РФ № 1693 н от 29.12.2012 г. об утверждении стандарта специализированной медицинской помощи при транзиторной ишемической атаке. Доступен с: https://www.rosminzdrav.ru/documents/8945-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1693n-ob-utverzhdenii-standarta-spetsia-lizirovannoy-meditsinskoy-pomoschi-pri-tranzitornoy-ishemi-cheskoy-atake [Russian Ministry of Health Order of 29.12.2012 № 1693n approving the specialized medical care standard for transient ischemic attack. Available at: https://www.rosminzdrav.ru/documents/8945-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1693n-ob-utverzhdeniistandarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-tranzitornoy-ishemicheskoy-atake. In Russian].

13. Приказ Министерства здравоохранения РФ № 1692 н от 29.12.2012 г. об утверждении стандарта специализированной медицинской помощи при внутримозговом кровоизлиянии (консервативное лечение). Доступен с: https://www.rosminzdrav.ru/documents/8969-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1692n-ob-utverzhdeniistandarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-vnutrimozgovom-krovoizliyanii-konservativnoe-lechenie. [Russian Ministry of Health Order of 29.12.2012 g № 1692n approving the specialized medical care standards in intracerebral hemorrhage (conservative treatment). Available at: https://www.rosminzdrav.ru/documents/8969-prikaz-ministerstva-zdravoohraneniyarossiyskoy-federatsii-ot-29-dekabrya-2012-g-1692n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschipri-vnutrimozgovom-krovoizliyanii-konservativnoe-lechenie. In Russian].

14. Приказ Министерства здравоохранения РФ № 1740 н от 29.12.2012 г. об утверждении стандарта специализированной медицинской помощи при инфаркте мозга. Доступен с: https://www.rosminzdrav.ru/documents/8970-prikaz-mini-sterstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1740n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-infarkte-mozga. [Russian Ministry of Health Order of 29.12.2012 № 1740n approving the specialized medical care standard in cerebral infarction. Available at: https://www.rosminzdrav.ru/documents/8970-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1740n-ob-utverzhdeniistandarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-infarktemozga. In Russian].

15. Приказ Министерства здравоохранения РФ № 1749 н от 29.12.2012 г. об утверждении стандарта специализированной медицинской помощи при субарахноидальном кровоизлиянии (консервативное лечение). Доступен c: http://base.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=145061&fld=134&dst=1000000001,0&rnd=0.02678298372872079. [Russian Ministry of Health Order of 29.12.2012 № 1749n approving the specialized medical care standard in subarachnoid hemorrhage (conservative treatment). Available at: http://base.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=145061&fld=134&dst=1000000001,0&rnd=0.02678298372872079. In Russian].

16. Кузник Б. И., Витковский Ю. А., Захарова М. Ю., Ключерева Н. Н., Роднина О. С., Солпов А. В. Агрегационная активность форменных элементов крови у больных сахарным диабетом 1-го и 2-го типа. Сахарный диабет. 2012;2:49–53. [Kuznik BI, Vitkovskii YA, Zakharova MY, Kluchereva NN, Rodnina OS, Solpov AV. Aggregation activity of blood cells in patients with diabetes mellitus type 1 and 2. Diabetes. 2012;2:49– 53. In Russian].

17. Агаркова С. А., Филатова О. В., Костюченко Г. И. Агрегационная активность тромбоцитов у женщин с сахарным диабетом второго типа при приеме ацетилсалициловой кислоты. Известия Алтайского государственного университета. 2014;15– 19. doi:10.14258/izvasu (2014)3.2–01. [Agarkova SA, Filato- va OV, Kostuchenko GI. Platelet aggregation activity in women with diabetes of the second type when receiving acetylsalicylic acid. The News of Altai State University. 2014;15–19. doi:10.14258/izvasu(2014)3.2–01. In Russian].


Review

For citations:


Rodionova O.V., Sorokoumov V.A., Vavilova T.V., Bogatenkova Yu.D., Mnuskina M.M., Krupotkina I.G., Isaeva L.A. CHANGES IN IMPEDANCE AGREGATOMETRY IN PATIENTS WITH A HISTORY OF STROKE RECEIVING ANTIPLATELET DRUGS. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2017;23(6):507-516. (In Russ.) https://doi.org/10.18705/1607-419X-2017-23-6-507-516

Views: 1231


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)